Menu Close

4,175 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Purchased by U.S. Capital Wealth Advisors LLC

view original post

U.S. Capital Wealth Advisors LLC acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 4,175 shares of the medical equipment provider’s stock, valued at approximately $611,000.

A number of other institutional investors have also made changes to their positions in ZBH. Tradition Wealth Management LLC purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $30,000. Tompkins Financial Corp purchased a new stake in Zimmer Biomet in the 3rd quarter worth about $36,000. Strategic Blueprint LLC purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $48,000. Isthmus Partners LLC purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $50,000. Finally, Covington Capital Management lifted its stake in Zimmer Biomet by 40.0% in the 2nd quarter. Covington Capital Management now owns 350 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 100 shares in the last quarter. 88.54% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:ZBH opened at $126.99 on Friday. The business has a 50 day moving average price of $132.82 and a 200 day moving average price of $145.67. Zimmer Biomet Holdings, Inc. has a twelve month low of $116.60 and a twelve month high of $180.36. The company has a market cap of $26.53 billion, a price-to-earnings ratio of 32.65, a PEG ratio of 2.65 and a beta of 1.24. The company has a quick ratio of 0.95, a current ratio of 1.81 and a debt-to-equity ratio of 0.51.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, November 4th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.76 by $0.05. Zimmer Biomet had a return on equity of 12.67% and a net margin of 10.39%. The firm had revenue of $1.92 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.39 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 31st. Shareholders of record on Tuesday, December 28th will be given a $0.24 dividend. The ex-dividend date of this dividend is Monday, December 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.76%. Zimmer Biomet’s dividend payout ratio is currently 24.68%.

Several equities research analysts recently issued reports on the company. JMP Securities reduced their price objective on Zimmer Biomet from $195.00 to $175.00 and set a “market outperform” rating for the company in a research note on Friday, November 5th. SVB Leerink reaffirmed an “outperform” rating on shares of Zimmer Biomet in a research report on Friday, October 22nd. Royal Bank of Canada assumed coverage on Zimmer Biomet in a research report on Thursday, December 9th. They issued a “sector perform” rating and a $140.00 target price on the stock. BTIG Research dropped their target price on Zimmer Biomet from $173.00 to $161.00 and set a “buy” rating on the stock in a research report on Friday, November 5th. They noted that the move was a valuation call. Finally, Needham & Company LLC lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating and dropped their target price for the stock from $175.00 to $158.00 in a research report on Thursday, December 9th. Five equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Buy” and an average price target of $174.48.

In other Zimmer Biomet news, insider Sang Yi sold 2,800 shares of the firm’s stock in a transaction that occurred on Tuesday, December 14th. The stock was sold at an average price of $124.14, for a total value of $347,592.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.56% of the stock is currently owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It operates through the following segments: Americas and Global Businesses, EMEA, and Asia Pacific. The Americas and Global Businesses segment consists of U.S. and includes other North, Central and South American markets for all product categories as well as the global results for the Dental products division.

Featured Article: Fundamental Analysis

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Want More Great Investing Ideas?